The right compound in the right assay at the right time: an integrated discovery DMPK strategy

References

• Amidon, G. L., Lennernas, H., Shah, V. P., Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–420.
   PubMed Web of Science ®Google Scholar
• Anderson, S., Luffer-Atlas, D., Knadle, M. P. (2009). Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243–256.
   PubMed Web of Science ®Google Scholar
• Afzelius, L., Hasselgren Arnby, C., Broo, A., Carlsson, L., Isaksson, C., Jurva, U., et al. (2007). State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistic insights, and future applications. Drug Metab Rev 39:61–86.
   PubMed Web of Science ®Google Scholar
• Arrowsmith, J. (2011a). Trial watch: phase III and submission failures: 2007–2010. Nat Rev Drug Disc 10:87.
   Web of Science ®Google Scholar
• Arrowsmith, J. (2011b). Trial watch: phase II failures: 2008–2010. Nat Rev Drug Disc 10:328–329.
   PubMed Web of Science ®Google Scholar
• Artursson, P., Karlsson, J. (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880–885.
   PubMed Web of Science ®Google Scholar
• Artursson, P., Palm, K., Luthman, K. (2001). Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27–43.
   PubMed Web of Science ®Google Scholar
• Avdeef, A. (2005). The rise of PAMPA. Expert Opin Drug Metab Toxicol 1:325–342.
   PubMedGoogle Scholar
• Baillie, T. A. (2006). Future of toxicology metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19:889–893.
   PubMed Web of Science ®Google Scholar
• Bell, L., Bickford, S., Nguyen, P. H., Wang, J., He, T., Zhang, B., et al. (2008). Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery. J Biomol Screen 13:343–353.
   PubMed Web of Science ®Google Scholar
• Berellini, G., Springer, C., Waters, N. J., Lombardo, R. (2009). In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. J Med Chem 52:4488–4495.
   PubMed Web of Science ®Google Scholar
• Beresford, A. P., Segall, M., Tarbit, M.H. (2004). In silico prediction of ADME properties: are we making progress, Curr Op Drug Dis Dev 7:36–42.
   PubMed Web of Science ®Google Scholar
• Bjornsson, T., Callaghan, J., Einolf, J. H., Fischer, V., Gan, L., Grimm, S., et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443–469.
   PubMed Web of Science ®Google Scholar
• Bortolato, M., Chen, K., Shih, J. C. (2008). Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 60:1527–1533.
   PubMed Web of Science ®Google Scholar
• Bredberg, U., Paalzow, L. (1990). Pharmacokinetics of methylergometrine in the rat: evidence for enterohepatic recirculation by a linked-rat model. Pharm Res 7:14–20.
   PubMed Web of Science ®Google Scholar
• Brown, C. D., Sayer, R., Windass, A. S., Haslam, I. S., De Broe, M. E., D’Haese, P. C., et al. (2008). Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol 233:428–438.
   PubMed Web of Science ®Google Scholar
• Cashman, J. R. (2008). Role of flavin-containing monooxygenase in drug development. Expert Opin Drug Metab Toxicol 4:1507–1521.
   PubMed Web of Science ®Google Scholar
• Chiba, M., Ishii, Y., Sugiyama, Y. (2009). Prediction of hepatic clearance in human from in vitro data for successful drug development. Am Assoc Pharm Sci J 11:262–276.
   Google Scholar
• Cohen, A. (2008). Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies. Clin Pharmacokinet 47:373–381.
   PubMed Web of Science ®Google Scholar
• Cossum, P. A. (1988). Role of the red blood cell in drug metabolism. Biopharm Drug Dispos 9:321–336.
   PubMed Web of Science ®Google Scholar
• Cruciani, G., Carosati, E., De Boeck, B., Ethirajulu, K., Mackie, C., Howe, T., et al. (2005). MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 48:6970–6979.
   PubMed Web of Science ®Google Scholar
• Cvetkovic, M., Leake, B, Fromm, M. F., Wilkinson, G. R., Kim R. B. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Met Disp 27:866–871.
   PubMed Web of Science ®Google Scholar
• Damle, B. D., Uderman, H., Biswas, P., Crownover, P., Lin, C., Glue, P. (2009). Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Br J Clin Pharmacol 68:682–689.
   PubMed Web of Science ®Google Scholar
• Danhof, M., Alvan, G., Dahl, S. G., Kuhlmann, J., Paintaud, G. (2005). Mechanism-based pharmacokinetic-pharmacodynamic modeling—a new classification of biomarkers. Pharm Res 22:1432–1437.
   PubMed Web of Science ®Google Scholar
• Darwich, S., Neuhoff, S., Jamei, M., Rostami-Hodjegan, A. (2010). Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the “Advanced dissolution, absorption, metabolism (ADAM)“ model. Curr Drug Met 11:716–729.
   PubMed Web of Science ®Google Scholar
• Davies, M. I. (1999). A review of microdialysis sampling for pharmacokinetic applications. Anal Chim Acta 379:227–249.
   Web of Science ®Google Scholar
• Dawson, S., Stahl, S., Paul, N., Barber, J., Kenna, J. G. (2012). In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Met Disp 40:130–138.
   PubMed Web of Science ®Google Scholar
• Di, L., Kerns, E. H. (2003). Profiling drug-like properties in discovery research. Curr Opin Chem Biol 7:402–408.
   PubMed Web of Science ®Google Scholar
• Di, L., Kerns, H., Carte, G. (2008). Strategies to assess blood-brain barrier penetration. Expert Opin Drug Discov 3:677–687.
   PubMed Web of Science ®Google Scholar
• Didziapetris, R., Japertas, P., Avdeef, A., Petrauskas, A. (2003). Classification analysis of P-glycoprotein substrate specificity. J Drug Target 11:391–406.
   PubMed Web of Science ®Google Scholar
• Doan, K. M. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, J. et al. (2002). Passive permeability and p-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharm Exp Ther 303:1029–1037.
   PubMed Web of Science ®Google Scholar
• Doddareddy, M. R., Cho, Y. S., Koh, H. Y., Kim, D. H., Pae, A. N. (2006). In silico renal clearance model using classical volsurf approach. J Chem Inf Model 46:1312–1320.
   PubMed Web of Science ®Google Scholar
• Doran, A., Obach, R. S., Smith, B. J., Hosea, N. A., Becker, S., Callegari, E., et al. (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165–174.
   PubMed Web of Science ®Google Scholar
• Eisenblatter, T., Galla, H. J. (2002). A new multidrug resistance protein at the blood–brain barrier. Biochem Biophys Res Comm 293:1273–1278.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2010). Guideline on the investigation of drug interactions. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf. Accessed on February 11, 2011.
   Google Scholar
• Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., Baillie, T. A. (2004). Drug−protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3–16.
   PubMed Web of Science ®Google Scholar
• Eyal, S., Hsiao, P., Unadkat, J. D. (2009). Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123:80–104.
   PubMed Web of Science ®Google Scholar
• Fagerholm, U. (2008). Prediction of human pharmacokinetics—biliary and intestinal clearance and enterohepatic circulation. J Pharm Pharmacol 60:535–542.
   PubMed Web of Science ®Google Scholar
• Fahmi, O. A., Boldt, S., Kish, M., Obach, R. S., Tremaine, L. M. (2008). Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dis 36:1971–1974.
   PubMed Web of Science ®Google Scholar
• Feng, B., LaPerle, J. L., Chang, G., Varma, M. V. S. (2010). Renal clearance in drug discovery and development: molecular descriptors, drug transporters, and disease state. Exp Opin Drug Metab Toxicol 6:939–952.
   PubMed Web of Science ®Google Scholar
• Fenner, K. S., Jones, H. M., Ullah, M., Kempshall, S., Dickins, M., Lai, Y., et al. (2012). The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica 42:28–45.
   PubMed Web of Science ®Google Scholar
• Fowler, S., Zhang, H. (2008). In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. Am Assoc Pharm Sci J 10:410–424.
   Google Scholar
• Fridén, M., Ducrozet, F., Middleton, B., Antonsson, M., Bredberg, U., Hammarlund-Udenaes, M. (2009a). Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos 37:1226–1233.
   PubMed Web of Science ®Google Scholar
• Fridén, M., Winiwarter, S., Jerndal, G., Bengtsson, O., Wan, H., Bredberg, U., et al. (2009b). Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233–6243.
   PubMed Web of Science ®Google Scholar
• Fridén, M., Ljungqvist, H., Middleton, B., Bredberg, U., Hammarlund-Udenaes, M. (2010). Improved measurement of drug exposure in brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab 30:150–161.
   PubMed Web of Science ®Google Scholar
• Fridén, M., Bergstrom, F., Wan, H., Rehngren, M., Ahlin, G., Hammarlund-Udenaes, M., et al. (2011). Measurement of unbound drug exposure in the brain: modelling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dis 39:353–362.
   PubMed Web of Science ®Google Scholar
• Gabrielsson, J., Green, A. R. (2009). Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther 331:767–774.
   PubMed Web of Science ®Google Scholar
• Gabrielsson, J., Dolgos, H., Gillberg, P. G., Bredberg, U., Benthem, B., Duker, G. (2009). Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov Today 14:358–372.
   PubMed Web of Science ®Google Scholar
• Gabrielsson, J., Green, A. R., Van der Graaf, P. H. (2010). Optimising in vivo pharmacology studies--Practical PKPD considerations. J Pharmacol Toxicol Methods 61:146–156.
   PubMed Web of Science ®Google Scholar
• Galetin, A., Gertz, M., Houston, J. B. (2008). Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909–922.
   PubMed Web of Science ®Google Scholar
• Garcia, M. J., Reinoso, R. F., Sanchez Navarro, A., Prous, J. R. (2003). Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 25:457–481.
   PubMed Web of Science ®Google Scholar
• Gertz, M., Harrison, A., Houston, J. B., Galetin, A. (2010). Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147–1158.
   PubMed Web of Science ®Google Scholar
• Ghibellini, G., Vasist, L. S., Leslie, E. M., Heizer, W. D., Kowalsky, R. J., Calvo, B. F., et al. (2007). In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin Pharmacol Ther 81:406–413.
   PubMed Web of Science ®Google Scholar
• Giacomini, K. M., Huang, S-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. M., Chu, X., et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Gleeson, P., Davis, A., Chohan, K., Paine, S., Boyer, S., Gavaghan, C. L., et al. (2007). Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models. J Comput Aided Mol Des 21:559–573.
   PubMed Web of Science ®Google Scholar
• Griffin, L., Annaert, P., Brouwer, K. L. R. (2011). Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci 100:3636–3654.
   PubMed Web of Science ®Google Scholar
• Grime, K. H., Bird, J., Ferguson, D., Riley, R. J. (2009). Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36:175–191.
   PubMed Web of Science ®Google Scholar
• Gu, X., Manautou, J. E. (2010). Regulation of hepatic ABCC transporters by xenobiotics and in disease states. Drug Metab Rev 42:482–538.
   PubMed Web of Science ®Google Scholar
• Guengerich, F. P. (2005). Principles of covalent binding of reactive metabolites and examples of activation of bis-electrophiles by conjugation. Arch Biochem Biophys 433:369–378.
   PubMed Web of Science ®Google Scholar
• Harmsen, S., Meijerman, I., Beijnen, J. H., Schellens, J. H. M. (2009). Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chem Pharm 64:35–43.
   PubMed Web of Science ®Google Scholar
• Hitchcock, S., Pennington, L. (2006). Structure-brain exposure relationships. J Med Chem 49:7559–7583.
   PubMed Web of Science ®Google Scholar
• Hirano, M., Maeda, K., Shitara, Y., Sugiyama, Y. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Disp 34:1229–1236.
   PubMed Web of Science ®Google Scholar
• Huang, S., Strong, J., Zhang, L., Reynolds, K., Nallani, S., Temple, R., et al. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–670.
   PubMed Web of Science ®Google Scholar
• Ito, K., Brown, H. S., Houston, J. B. (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharm 57:473–486.
   PubMed Web of Science ®Google Scholar
• Jana, S., Mandlekar, S. (2009). Role of phase II drug metabolizing enzymes in cancer chemoprevention. Curr Drug Metab 10:595–616.
   PubMed Web of Science ®Google Scholar
• Johnson, T. W., Dress, K. R., Edwards, M. (2009). Using the golden triangle to optimise clearance and oral absorption. Bioorg Med Chem Lett 19:5560–5564.
   PubMed Web of Science ®Google Scholar
• Johnson, K. C., Swindell, A. C. (1996). Guidance in the setting of drug particle size specifications to minimise variability in absorption. Pharm Res 13:1795–1798.
   PubMed Web of Science ®Google Scholar
• Ju, C., Uetrecht, J. P. (2002). Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding, and the regulation of the immune system. Curr Drug Metab 3:367–377.
   PubMedGoogle Scholar
• Kandel, E. R., Schwartz, J. H., Jessel, T. M. (2000). Principles of neural science, 4th ed. New York: McGraw-Hill.
   Google Scholar
• Kanebratt, K. P., Andersson, T. B. (2008). HepaRG cells as an in vitro model for evaluation of cytochrome. Drug Metab Disp 36:137–145.
   PubMed Web of Science ®Google Scholar
• Kerns, E. H., Li, D. (2003). Pharmaceutical profiling in drug discovery. Drug Disc Today 8:316–323.
   PubMed Web of Science ®Google Scholar
• Kiang, T. K. L., Ensom, M. H. H., Chang, T. K. H. (2005). UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97–132.
   PubMed Web of Science ®Google Scholar
• Kola, I., Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates. Nat Rev Drug Dis 3:711–716.
   PubMed Web of Science ®Google Scholar
• Ku, W. K., Bigger, A., Brambilla, G., Glatt, H., Gocke, E., Guzzie, P. J., et al. (2007). Strategy for genotoxicity testing-metabolic considerations. Mutat Res 627:59–77.
   PubMed Web of Science ®Google Scholar
• Kusuhara, H., Sugiyama, Y. (2010). Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters. Drug Metab Rev 42:539–550.
   PubMed Web of Science ®Google Scholar
• de Lange, E. C., Danhof, M., de Boer, A. G., Breimer, D. D. (1997). Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Rev 25:27–49.
   PubMed Web of Science ®Google Scholar
• Lappin, G., Garner, R. C. (2008). The utility of microdosing over the past 5 years. Exp Op Drug Met Tox 4:1499–1506.
   PubMed Web of Science ®Google Scholar
• Lavé, T., Chapman, K., Goldsmith, P., Rowland, M. (2009). Human clearance prediction: shifting the paradigm. Expert Opin Drug Metab Toxicol 5:1039–1048.
   PubMed Web of Science ®Google Scholar
• LeCluyse, E. L. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343–368.
   PubMed Web of Science ®Google Scholar
• Li, N., Bi, Y. A., Duignan, D. B., Lai, Y. (2009). Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol Pharmacol 6:1180–1189.
   PubMed Web of Science ®Google Scholar
• Lin, J. H., Lu, A. Y. H. (1998). Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharm 35:361–390.
   Google Scholar
• Lindberg, P., Nordberg, P., Alminger, T., Brändström, A., Wallmark, B. (1986). The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem 29:1327–1329.
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25.
   Web of Science ®Google Scholar
• Luo, G., Johnson, S., Hsueh, M-M., Zheng, J., Cai, H., Xin, B., et al. (2010). In silico prediction of biliary excretion of drugs in rats based on physicochemical properties. Drug Metab Dis 38:422–430.
   PubMed Web of Science ®Google Scholar
• Mahmood, I. (1998). Interspecies scaling of renally secreted drugs. Life Sci 63:2365–2371.
   PubMed Web of Science ®Google Scholar
• Mahmood, I. (2005). Interspecies scaling of biliary excreted drugs: a comparison of several methods. J Pharm Sci 94:883–892.
   PubMed Web of Science ®Google Scholar
• Mazur, C. S., Kenneke, J. F., Goldsmith, M. R., Brown, C. (2009). Contrasting influence of NADPH and a NADPH-regenerating system on the metabolism of carbonyl-containing compounds in hepatic microsomes. Drug Metab Dispos 37:1801–1805.
   PubMed Web of Science ®Google Scholar
• McGinnity, D. F., Collington, J., Austin, R. P., Riley, R. J. (2007). Evaluation of human pharmacokinetics, therapeutic dose, and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463–479.
   PubMed Web of Science ®Google Scholar
• McGinnity, DF, Zhang, G, Kenny, JR, Hamilton, GA, Otmani, S, Stams, KR, et al. (2009). Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Disp 37:1259–1268.
   PubMed Web of Science ®Google Scholar
• Miller, E. C., Miller, J. A. (1966). Mechanisms of chemical carcinogenesis: nature of proximate carcinogens and interactions with macromolecules. Pharmacol Rev 18:805–838.
   PubMed Web of Science ®Google Scholar
• Nassar, A. E., Kame, A. M., Clarimont, C. (2004). Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Dis Today 9:1020–1028.
   PubMed Web of Science ®Google Scholar
• Nelson, S. D., Pearson, P. G. (1990). Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals. Ann Rev Pharmacol Toxicol 30:169–195.
   PubMed Web of Science ®Google Scholar
• Nestorov, I. A., Aarons, L. J., Arundel, P. A., Rowland, M. (1998). Lumping of whole-body physiologically based pharmacokinetic models. J Pharmaco Biopharm 26:21–46.
   PubMedGoogle Scholar
• Obach, R. S., Walsky, R. L., Venkatakrishnan, K. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Met Disp 35:246–255.
   PubMed Web of Science ®Google Scholar
• Obach, R. S. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomes intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–1359.
   PubMed Web of Science ®Google Scholar
• Obach, R. S., Lombardo, F., Waters, N. J. (2008). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–1405.
   PubMed Web of Science ®Google Scholar
• Oie, S., Tozer, T. N. (1979). Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68:1203–1205.
   PubMed Web of Science ®Google Scholar
• Paine, S. W., Barton, P., Bird, J., Denton, R., Menochet, K., Smith, A., et al. (2010). A rapid computational filter for predicting the rate of human renal clearance. J Mol Graphics Mod 29:529–537.
   PubMed Web of Science ®Google Scholar
• Polli, J. W., Jarrett, J. J., Studenberg, S. D., Humphreys, J. E., Dennis, S. W., Brouwer, K. R., et al. (1999). Role of p-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206–1212.
   PubMed Web of Science ®Google Scholar
• Poulin, P., Theil, F. P. (2009). Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 98:4941–4961.
   PubMed Web of Science ®Google Scholar
• Poulin, P., Jones, H. M., Jones, R. D., Yates, J. W., Gibson, C. R., Chien, J. Y., et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets. J Pharm Sci 2011 Apr 26. doi: 10.1002/jps.22554.
   Web of Science ®Google Scholar
• Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., et al. (2008). Prodrugs: design and clinical applications. Nat Rev Drug Discov 7:255–270.
   PubMed Web of Science ®Google Scholar
• Rawden, H. C., Carlile, D. J., Tindall, A., Halifax, D., Galetin, A., Ito, K., et al. (2005). Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica 35:603–625.
   PubMed Web of Science ®Google Scholar
• Read, K. D., Braggio, S. (2010). Assessing brain free fraction in early drug discovery. Expert Opin Drug Metab Toxicol 6:337–344.
   PubMed Web of Science ®Google Scholar
• Riley, R. J., Grime, K., Weaver, R. (2007). Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3:51–66.
   PubMed Web of Science ®Google Scholar
• Riley, R. J., McGinnity, D. F., Austin, R. P. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304–1311.
   PubMed Web of Science ®Google Scholar
• Rodgers, T., Rowland, M. (2007). Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24:918–933.
   PubMed Web of Science ®Google Scholar
• Rowland, M., Tozer, T. N. (1989). Clinical pharmacokinetics: concepts and applications, 2nd ed. London: Lea and Febiger.
   Google Scholar
• Rowland, M., Peck, C., Tucker, G. (2011). Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 10:45–73.
   Google Scholar
• Shitara, Y., Horie, T., Sugiyama, Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425–446.
   PubMed Web of Science ®Google Scholar
• Sills, G. J., Kwan, P., Butler, E., de Lange, E. C. M., van den Berg, D-J., Brodie, M. J. (2002). P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epil Behav 3:427–432.
   PubMed Web of Science ®Google Scholar
• Smith, D. A., Jones, B. C., Walker, D. K. (1996). Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16:243–266.
   PubMed Web of Science ®Google Scholar
• Smith, D. A. (2007). Do prodrugs deliver? Curr Opin Drug Discov Devel 10:550–559.
   PubMed Web of Science ®Google Scholar
• Smith, D. A., Di, L., Kerns, E. H. (2010). The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Disc 9:929–939.
   PubMed Web of Science ®Google Scholar
• Soars, M. G., Grime, K., Sproston, J. L., Webborn, P. J., Riley, R. J. (2007). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859–865.
   PubMed Web of Science ®Google Scholar
• Soars, M. G., Webborn, P. J., Riley, R. J. (2009). Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol Pharmacol 6:1662–1677.
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck, A-K., Jones, C., Ferguson, D., Middleton, B. J., Projean, D., Floby, E., et al. (2012). Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 2012 Apr 18. doi: 10.3109/00498254.2012.669080.
   PubMed Web of Science ®Google Scholar
• Sun, H., Scott, D. O. (2010). Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 75:3–17.
   PubMed Web of Science ®Google Scholar
• Szakács, G., Váradi, A., Özvegy-Laczka, C., Sarkadi, B. (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion, and toxicity (ADME–Tox). Drug Disc Today 13:379–393.
   PubMed Web of Science ®Google Scholar
• Takahashi, M., Washio, T., Suzuki, N., Igeta, K., Yamashita, S. (2009). The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 98:4343–4353.
   PubMed Web of Science ®Google Scholar
• Tang, H., Mayersohn, M. (2011). Controversies in allometric scaling for predicting human drug clearance: an historical problem and reflections on what works and what does not. Curr Top Med Chem 11:340–350.
   PubMed Web of Science ®Google Scholar
• Tang, F., Horie, K., Borchardt, R. T. (2002). Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19:765–772.
   PubMed Web of Science ®Google Scholar
• Testa, B. (2009). Drug metabolism for the perplexed medicinal chemist. Chem Biodivers 6:2055–2070.
   PubMed Web of Science ®Google Scholar
• Thompson, R. A., Isin, E. M., Li, Y., Weaver, R., Weidolf, L., Wilson, I., et al. (2011). Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interac 19:65–71.
   Google Scholar
• Tucker, G. T. (1981). Measurement of the renal clearance of drugs. Br J Clin Pharmacol 12:761–770.
   PubMed Web of Science ®Google Scholar
• Ungell, A-L., Nylander, S., Bergstrand, S., Sjöberg, Å., Lennernäs, H. (1998). Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 87:360–366.
   PubMed Web of Science ®Google Scholar
• Ungell, A-L., Artursson, P. (2009). An overview of Caco-2 and alternatives for prediction of intestinal drug transport and absorption.. In: van de Waterbeemd, H., Testa, B., (Eds.), Drug bioavailability: estimation of solubility, permeability, absorption and bioavailability, 2nd ed. (pp. 133–159). Weinheim, Germany: Wiley-VCH.
   Google Scholar
• U.S. Food and Drug Administration. Guidance for industry: drug metabolism/drug interactions in the drug development process: studies in vitro. (1997). Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072104.pdf. Accessed on February 10, 2011.
   Google Scholar
• U.S. Food and Drug Administration. (2006). Draft guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf. Accessed on February 10, 2011.
   Google Scholar
• U.S. Food and Drug Administration. (2008). Guidance for industry: safety testing of drug metabolites. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf. Accessed on February 11, 2011.
   Google Scholar
• Varma, M. V. S., Feng, B., Obach, R. S., Troutman, M. D., Chupka, J., Miller, H. R., et al. (2009). Physicochemical determinants of human renal clearance. J Med Chem 52:4844–4852.
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd, H., Smith, D. A., Jones, B. C. (2001). Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des 15:273–286.
   PubMed Web of Science ®Google Scholar
• Wan, H., Rehngren, M., Giordanetto, F., Bergström, F., Tunek, A. (2007). High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50:4606–4615.
   PubMed Web of Science ®Google Scholar
• Ward, P. (2008). Importance of drug transporters in pharmacokinetics and drug safety. Toxicol Mech Methods 18:1–10.
   PubMed Web of Science ®Google Scholar
• Waring, M. J. (2009). Defining optimum lipophilicity and molecular weight ranges for drug candidates—molecular weight dependent lower logD limits based on permeability. Bioorg Med Chem Lett 19:2844–2851.
   PubMed Web of Science ®Google Scholar
• Waring, M. J. (2010). Lipophilicity in drug discovery. Expert Opin Drug Discov 5:235–248.
   PubMed Web of Science ®Google Scholar
• Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., Leeson, P. D. (2003). A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 46:1250–1256.
   PubMed Web of Science ®Google Scholar
• Williams, J., Hyland, R., Jones, B., Smith, D., Hurts, S., Goosen, T., et al. (2004a). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–1208.
   PubMed Web of Science ®Google Scholar
• Williams, P. A., Cosme, J., Vinkovic, D. M., Ward, A., Angove, H. C., Day, P. J., et al. (2004b). Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683–686.
   PubMed Web of Science ®Google Scholar
• Wu, C-Y., Benet, L. Z. (2005). Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11–23.
   PubMed Web of Science ®Google Scholar
• Yamashita, F., Hashida, M. (2004). In silico approaches for predicting ADME properties of drugs. Drug Met and Pharmaco 19:327–338.
   PubMedGoogle Scholar
• Yamazaki, M., Kobayashi, K., Sugiyama, Y. (1996). Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. Biopharm Drug Dispos 17:607–621.
   PubMed Web of Science ®Google Scholar
• Yang, X., Gandhi, Y. A., Duignan, D. B., Morris, M. E. (2009). Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. Am Assoc Pharm Sci J 11:511–525.
   Google Scholar
• Yu, D. K. (1999). The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203–1211.
   PubMed Web of Science ®Google Scholar
• Zhou, D., Afzelius, L., Grimm, S. W., Andersson, T. B., Zauhar, R. J., Zamora, I. (2006). Comparison of methods for the prediction of the metabolic site for CYP3A4-mediated metabolic reactions. Drug Metab Dis 34:976–983.
   PubMed Web of Science ®Google Scholar
• Zhou, S-F. (2008). Structure, function, and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38:802–832.
   PubMed Web of Science ®Google Scholar
• Zhou, S-F. (2009a). Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48:689–723.
   PubMed Web of Science ®Google Scholar
• Zhou, S-F. (2009b). Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48:761–804.
   PubMed Web of Science ®Google Scholar